TABLE 3. Annual reported cases of notifiable diseases, by month*, United States, excluding U.S. Territories and Non-U.S. Residents, 2022 column labels in same order that data fields appears in each record below: Disease Jan. Feb. Mar. Apr. May June July Aug. Sept. Oct. Nov. Dec. Unknown Total tab delimited data: Anthrax — — — — — — — — — — — — — — Arboviral diseases, Chikungunya virus disease 7 3 7 4 1 6 7 10 9 13 5 9 — 81 Arboviral diseases, Eastern equine encephalitis virus disease, Neuroinvasive — — — — — — — 1 — — — — — 1 Arboviral diseases, Eastern equine encephalitis virus disease, Non-neuroinvasive — — — — — — — — — — — — — — Arboviral diseases, Jamestown Canyon virus disease, Neuroinvasive — — — — 1 2 1 2 1 3 1 — — 11 Arboviral diseases, Jamestown Canyon virus disease, Non-neuroinvasive — — — 1 — — — — — — — — — 1 Arboviral diseases, La Crosse virus disease, Neuroinvasive — — — — — — 6 4 7 1 1 — — 19 Arboviral diseases, La Crosse virus disease, Non-neuroinvasive — — — — — — 1 — 1 1 — — — 3 Arboviral diseases, Powassan virus disease, Neuroinvasive — 1 1 2 5 8 10 3 1 3 7 1 — 42 Arboviral diseases, Powassan virus disease, Non-neuroinvasive — — — 1 1 — — — — 2 — — — 4 Arboviral diseases, St. Louis encephalitis virus disease, Neuroinvasive — 1 — — — 4 3 5 4 5 4 2 — 28 Arboviral diseases, St. Louis encephalitis virus disease, Non-neuroinvasive — — — — — — — 2 2 — 2 — — 6 Arboviral diseases, West Nile virus disease, Neuroinvasive 4 2 — 2 3 12 67 253 304 145 21 15 — 828 Arboviral diseases, West Nile virus disease, Non-neuroinvasive 2 2 3 2 4 6 29 109 104 39 8 2 — 310 Arboviral diseases, Western equine encephalitis virus disease, Neuroinvasive — — — — — — — — — — — — — — Arboviral diseases, Western equine encephalitis virus disease, Non-neuroinvasive — — — — — — — — — — — — — — Babesiosis, Total 9 16 18 39 62 227 838 412 204 132 82 72 — 2,111 Babesiosis, Confirmed 6 9 13 28 49 195 754 377 176 87 64 54 — 1,812 Babesiosis, Probable 3 7 5 11 13 32 84 35 28 45 18 18 — 299 Botulism, Total 15 12 8 21 12 19 21 19 27 11 16 16 — 197 Botulism, Foodborne 1 — — — 1 2 — 1 1 — — — — 6 Botulism, Infant 13 11 8 19 10 15 17 16 18 7 15 14 — 163 Botulism, Other (wound & unspecified) 1 1 — 2 1 2 4 2 8 4 1 2 — 28 Brucellosis 11 4 9 12 14 12 20 8 11 13 3 9 — 126 Campylobacteriosis 3,083 3,638 4,134 5,728 5,245 6,219 8,323 6,396 6,129 7,023 4,887 5,808 — 66,613 Candida auris, clinical † 95 78 69 65 48 67 66 85 89 105 96 138 — 1,001 Carbapenemase-producing carbapenem-resistant Enterobacteriaceae 143 211 218 240 211 197 247 249 249 313 234 306 — 2,818 Chancroid — — — — — — — 1 — — — — — 1 Chlamydia trachomatis infection § 115,433 128,956 132,998 165,538 129,892 122,547 159,369 134,272 129,342 162,433 118,726 150,078 — 1,649,584 Cholera — 1 — 4 1 2 2 — — 1 1 — — 12 Coccidioidomycosis 1,473 1,307 1,148 1,701 1,613 1,404 2,039 1,260 1,321 1,437 1,293 1,616 — 17,612 Coronavirus Disease 2019 (COVID-19), Total 18,537,709 3,374,286 764,989 1,386,788 2,807,834 2,963,968 4,051,734 2,827,843 1,663,122 1,299,123 1,238,476 2,202,006 14,917 43,132,795 Coronavirus Disease 2019 (COVID-19), Confirmed 15,242,207 2,639,104 592,059 1,147,267 2,280,462 2,346,849 3,139,250 2,112,462 1,233,301 984,486 935,847 1,615,898 8,212 34,277,404 Coronavirus Disease 2019 (COVID-19), Probable ¶ 3,295,502 735,182 172,930 239,521 527,372 617,119 912,484 715,381 429,821 314,637 302,629 586,108 6,705 8,855,391 Cryptosporidiosis, Total 535 623 749 1,100 906 989 1,521 1,463 1,440 1,383 871 1,026 — 12,606 Cryptosporidiosis, Confirmed 407 488 611 868 738 801 1,240 1,209 1,176 1,122 691 818 — 10,169 Cryptosporidiosis, Probable 128 135 138 232 168 188 281 254 264 261 180 208 — 2,437 Cyclosporiasis 7 9 12 26 151 484 1,288 675 162 121 102 54 — 3,091 Dengue virus infections, Dengue ** 35 14 19 22 30 35 136 264 302 310 132 155 — 1,454 Dengue virus infections, Dengue-like illness ** — — — 2 — — 1 10 6 5 4 5 — 33 Dengue virus infections, Severe dengue ** — — — 1 — 1 2 8 15 6 5 5 — 43 Diphtheria — — — — — — — — — — 1 — — 1 Ehrlichiosis and Anaplasmosis, Anaplasma phagocytophilum infection 19 13 42 293 603 1,420 1,377 461 259 364 526 274 — 5,651 Ehrlichiosis and Anaplasmosis, Ehrlichia chaffeensis infection 4 5 11 60 162 345 449 203 137 96 36 61 — 1,569 Ehrlichiosis and Anaplasmosis, Ehrlichia ewingii infection — — — — — 8 12 3 1 — 1 — — 25 Ehrlichiosis and Anaplasmosis, Undetermined ehrlichiosis/anaplasmosis — — 2 6 6 23 33 9 5 2 6 3 — 95 Giardiasis 765 987 941 1,213 977 994 1,388 1,327 1,396 1,496 1,170 1,165 — 13,819 Gonorrhea 49,634 51,235 51,553 63,934 50,712 49,956 64,437 51,753 50,167 61,971 45,306 57,352 — 648,010 Haemophilus influenzae, invasive disease, All ages, all serotypes 342 270 290 416 389 428 447 351 364 545 550 944 — 5,336 Haemophilus influenzae, invasive disease, Age <5 years, Serotype b — 1 — 2 — — 3 3 2 3 3 — — 17 Haemophilus influenzae, invasive disease, Age <5 years, Non-b serotype 11 7 15 17 15 8 13 9 7 17 11 10 — 140 Haemophilus influenzae, invasive disease, Age <5 years, Nontypeable 13 9 6 22 13 20 22 14 19 42 31 43 — 254 Haemophilus influenzae, invasive disease, Age <5 years, Unknown serotype 19 17 11 22 15 31 27 14 19 33 33 32 — 273 Hansen's disease 5 2 7 10 4 5 5 1 3 6 4 10 — 62 Hantavirus infection, non-hantavirus pulmonary syndrome †† — — — — — — — — — — — — — — Hantavirus pulmonary syndrome — — — 2 1 2 1 — 1 1 2 1 — 11 Hemolytic uremic syndrome post-diarrheal 9 11 12 26 19 28 42 54 30 30 20 31 — 312 Hepatitis, Viral Disease, Hepatitis A §§ 233 243 235 298 212 183 206 136 147 140 119 112 — 2,264 Hepatitis, Viral Disease, Hepatitis B, Acute §§ 113 172 165 237 168 166 224 133 176 200 127 245 — 2,126 Hepatitis, Viral Disease, Hepatitis B, Perinatal infection §§ — 1 1 3 2 — 1 1 — — 1 3 — 13 Hepatitis, Viral Disease, Hepatitis C, Acute §§ 350 424 536 633 447 431 471 457 418 508 360 593 — 5,628 Confirmed 303 362 446 541 394 370 403 407 362 441 307 512 — 4,848 Probable 47 62 90 92 53 61 68 50 56 67 53 81 — 780 Hepatitis, Viral Disease, Hepatitis C, Perinatal infection §§ 10 15 18 17 14 23 30 13 15 22 9 11 — 197 Human immunodeficiency virus diagnoses 2,724 2,827 3,461 3,072 3,163 3,278 3,199 3,672 3,320 3,038 2,993 2,888 28 37,663 Influenza-associated pediatric mortality 3 3 6 10 1 6 2 1 5 7 12 60 — 116 Invasive pneumococcal disease, All ages ¶¶ 1,665 1,205 1,228 1,898 1,415 1,179 925 647 879 1,665 1,869 3,787 — 18,362 Invasive pneumococcal disease, All ages, Confirmed ¶¶ 1,642 1,184 1,210 1,855 1,374 1,150 898 628 861 1,623 1,821 3,670 — 17,916 Invasive pneumococcal disease, All ages, Probable ¶¶ 23 21 18 43 41 29 27 19 18 42 48 117 — 446 Invasive pneumococcal disease, Age <5 years ¶¶ 71 47 70 100 99 73 66 50 67 153 126 195 — 1,117 Invasive pneumococcal disease, Age <5 years, Confirmed ¶¶ 71 45 69 97 98 70 64 49 65 147 123 180 — 1,078 Invasive pneumococcal disease, Age <5 years, Probable ¶¶ — 2 1 3 1 3 2 1 2 6 3 15 — 39 Legionellosis 376 307 351 437 501 823 961 807 951 852 536 610 — 7,512 Leptospirosis 3 2 1 4 2 4 8 11 3 13 3 8 — 62 Listeriosis, Total *** 55 65 45 80 78 74 126 116 96 109 66 53 — 963 Listeriosis, Confirmed *** 53 55 39 77 74 72 116 111 90 104 63 48 — 902 Listeriosis, Probable *** 2 10 6 3 4 2 10 5 6 5 3 5 — 61 Lyme disease, Total ††† 2,244 2,494 2,440 3,565 3,924 7,808 13,658 8,448 5,263 5,110 3,568 3,906 — 62,428 Lyme disease, Confirmed ††† 55 69 58 99 129 419 574 249 152 117 75 70 — 2,066 Lyme disease, Probable ††† 2,189 2,425 2,382 3,466 3,795 7,389 13,084 8,199 5,111 4,993 3,493 3,836 — 60,362 Malaria 123 116 81 98 112 128 260 218 261 223 125 187 — 1,932 Measles, Total §§§ — 3 — — 1 4 — 4 13 12 29 55 — 121 Measles, Indigenous §§§ — 1 — — — 1 — — 5 8 29 54 — 98 Measles, Imported §§§ — 2 — — 1 3 — 4 8 4 — 1 — 23 Meningococcal disease, All serogroups 25 29 23 26 26 21 23 17 21 33 29 39 — 312 Meningococcal disease, Serogroups ACWY 14 19 9 15 16 12 8 10 10 15 17 23 — 168 Meningococcal disease, Serogroup B 5 4 8 4 3 — 2 4 3 3 3 8 — 47 Meningococcal disease, Other serogroups 1 1 2 1 2 — 1 — 4 3 3 2 — 20 Meningococcal disease, Unknown serogroup 5 5 4 6 5 9 12 3 4 12 6 6 — 77 Mpox ¶¶¶ — — — — 28 517 7,688 11,099 6,249 2,788 950 502 — 29,821 Mumps 17 18 15 33 35 36 20 20 25 43 38 86 — 386 Novel Influenza A virus infections — 1 — 1 — — — 5 3 2 — — — 12 Pertussis 151 145 196 247 270 215 219 201 227 393 392 388 — 3,044 Plague **** — — — — — — — — — — — — — — Poliomyelitis, paralytic — — — — — — — 1 — — — — — 1 Poliovirus infection, nonparalytic — — — — — — — — — — — — — — Psittacosis — — — — 2 2 1 — — 1 — 1 — 7 Q fever, Total 8 16 26 31 14 11 18 17 17 16 8 12 — 194 Q fever, Acute 8 16 25 27 13 9 17 13 16 11 8 8 — 171 Q fever, Chronic — — 1 4 1 2 1 4 1 5 — 4 — 23 Rabies, Animal 165 161 243 295 348 369 348 486 428 287 243 182 3 3,558 Rabies, Human — — — — — — — — — — — — — — Rubella — — — 1 2 1 — — — 1 — 2 — 7 Rubella, congenital syndrome — — — — — — — — — — — — — — Salmonella Paratyphi infection †††† 10 12 11 10 2 5 12 10 15 11 3 29 — 130 Salmonella Typhi infection §§§§ 31 27 47 44 26 31 44 57 58 31 18 28 — 442 Salmonellosis (excluding S. Typhi infection and S. Paratyphi infection) ¶¶¶¶ 2,016 1,954 2,391 3,845 3,859 4,740 7,772 6,833 7,323 7,067 4,011 4,318 — 56,129 Severe acute respiratory syndrome-associated coronavirus disease — — — — — — — — — — — — — — Shiga toxin-producing Escherichia coli (STEC) 577 718 851 1,524 1,324 1,635 2,180 1,987 1,695 1,622 1,042 1,251 — 16,406 Shigellosis 767 874 950 1,279 1,062 1,112 1,565 1,420 1,370 1,768 1,170 1,407 — 14,744 Smallpox — — — — — — — — — — — — — — Spotted fever rickettsiosis, Total 29 23 22 64 173 207 280 154 145 107 43 45 — 1,292 Spotted fever rickettsiosis, Confirmed — — — 1 8 10 16 2 7 — 2 1 — 47 Spotted fever rickettsiosis, Probable 29 23 22 63 165 197 264 152 138 107 41 44 — 1,245 Streptococcal toxic shock syndrome 9 26 15 21 21 24 19 15 14 38 24 107 — 333 Syphilis, Total, all stages ***** 14,438 15,955 16,506 20,482 16,025 15,326 20,317 17,470 16,623 20,478 14,869 18,734 — 207,223 Syphilis, Congenital ††††† 307 270 314 263 279 295 338 352 317 340 342 338 — 3,755 Syphilis, Primary and secondary 4,165 4,508 4,778 6,008 4,493 4,345 6,168 5,090 4,867 5,581 3,991 5,016 — 59,010 Tetanus — 2 2 1 3 5 2 3 1 3 3 1 — 26 Toxic shock syndrome (other than Streptococcal) 4 3 4 2 — 1 3 4 2 3 2 3 — 31 Trichinellosis — — — — — — 5 4 — — — — — 9 Tuberculosis 394 502 600 829 623 704 780 680 609 849 652 1,109 — 8,331 Tularemia — 4 7 6 22 28 34 18 8 16 6 18 — 167 Vancomycin-intermediate Staphylococcus aureus 1 4 8 8 9 7 10 5 8 10 6 6 — 82 Vancomycin-resistant Staphylococcus aureus §§§§§ — — — 1 1 — — — — — — — — 2 Varicella morbidity 270 272 356 516 390 293 314 289 347 445 374 482 — 4,348 Varicella mortality — — — — 1 — 1 — 1 — — — — 3 Vibriosis, Total 97 121 137 222 185 242 455 501 364 346 189 179 — 3,038 Vibriosis, Confirmed 33 37 38 80 87 116 247 296 197 189 88 66 — 1,474 Vibriosis, Probable 64 84 99 142 98 126 208 205 167 157 101 113 — 1,564 Viral hemorrhagic fevers, Chapare virus ¶¶¶¶¶ — — — — — — — — — — — — — — Viral hemorrhagic fevers, Crimean-Congo hemorrhagic fever virus ****** — — — — — — — — — — — — — — Viral hemorrhagic fevers, Ebola virus ****** — — — — — — — — — — — — — — Viral hemorrhagic fevers, Guanarito virus ****** — — — — — — — — — — — — — — Viral hemorrhagic fevers, Junin virus ****** — — — — — — — — — — — — — — Viral hemorrhagic fevers, Lassa virus ****** — — — — — — — — — — — — — — Viral hemorrhagic fevers, Lujo virus ****** — — — — — — — — — — — — — — Viral hemorrhagic fevers, Machupo virus ****** — — — — — — — — — — — — — — Viral hemorrhagic fevers, Marburg virus ****** — — — — — — — — — — — — — — Viral hemorrhagic fevers, Sabia virus ****** — — — — — — — — — — — — — — Yellow fever — — — — — — — — — — — — — — Zika virus, Zika virus disease, congenital †††††† — — — — — — 1 — — — — — — 1 Zika virus, Zika virus disease, non-congenital 1 — 1 — — 2 1 — — — — — — 5 Zika virus, Zika virus infection, congenital †††††† — — — — — — — — — — — — — — Zika virus, Zika virus infection, non-congenital — — 1 — — — 1 — — — — — — 2 —: No reported cases - The reporting jurisdiction did not submit any cases to CDC. * Month is defined using MMWR week (https://ndc.services.cdc.gov/wp-content/uploads/2021/02/MMWR_Week_overview.pdf). MMWR week calendars can be found at https://ndc.services.cdc.gov/event-codes-other-surveillance-resources/. † Note that Candida auris colonization/screening cases are not included in this table. Additionally, there may be case count discrepancies of Candida auris clinical cases reported by the NNDSS and the CDC's Mycotic Diseases Branch due to differences in data sources, reporting and aggregation methods. Please refer to the Mycotic Diseases Branch's Tracking C. auris | Candida auris (C. auris) | CDC for Candida auris case data reported by jurisdictions. These data are submitted to the CDC separately of NNDSS by jurisdictions and are published by location of the facility. Please also see Note #8. § Beginning in January 2022, only confirmed cases are published to align with the approved CSTE position statement 21-ID-06, whereas in previous years, all case classification statuses were published. This change may cause a decrease in published case counts when compared to previous years. ¶ Of the reporting areas that submitted 2022 aggregate COVID-19 data to CDC, three did not submit probable cases. American Samoa, New York (excluding New York City), and U.S. Virgin Islands did not collect probable cases. ** Counts include confirmed and probable dengue cases. †† Case counts may include Old World hantavirus infections, such as Seoul virus. §§ Chronic hepatitis B and chronic hepatitis C data are not included in NNDSS tables but reported case counts are included in the annual Viral Hepatitis Surveillance Report, 2022, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/SurveillanceRpts.htm. ¶¶ Counts include drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years. *** Before 2019, probable cases were not reported, and cases in neonates ≤60 days of age were counted as one case in a mother-infant pair. Beginning in 2019, confirmed and probable cases are being reported, and maternal and neonatal cases are being counted separately. ††† For surveillance reporting purposes, jurisdictions are grouped into high- and low-incidence categories. Confirmed cases are only reported from low-incidence jurisdictions; however, probable cases are reported from both high- and low-incidence jurisdictions. For more information on jurisdiction classifications, visit https://www.cdc.gov/lyme. Currently, high-incidence jurisdictions include Connecticut, Delaware, Maine, Maryland, Massachusetts, Minnesota, New Hampshire, New Jersey, New York (excluding New York City), New York City, Pennsylvania, Rhode Island, Vermont, Virginia, West Virginia, Wisconsin, and the District of Columbia. §§§ Measles is considered imported if the disease was acquired outside of the United States and is considered indigenous if the disease was acquired anywhere within the United States or it is not known where the disease was acquired. ¶¶¶ CSTE adopted Mpox as a nationally notifiable condition on June 23, 2022 and beginning August 1, 2022 confirmed and probable cases are published to align with the CSTE position statement 22-ID-10. Case classifications for cases reported prior to August 1, 2022 should not have been retroactively changed based on the case definition in the CSTE position statement 22-ID-10. **** Beginning in 2020, confirmed and probable plague cases began to be combined and published. †††† Beginning in January 2019, cases began to be reported as Salmonella Paratyphi infection. In 2018, cases were reported as paratyphoid fever. Prior to 2018, cases of paratyphoid fever were considered salmonellosis. §§§§ Beginning in January 2019, cases began to be reported as Salmonella Typhi infection. In previous years, cases were reported as typhoid fever. ¶¶¶¶ Beginning in January 2019, cases began to be reported as salmonellosis (excluding Salmonella Typhi infection and Salmonella Paratyphi infection). In 2018, cases were reported as salmonellosis (excluding paratyphoid fever and typhoid fever). Prior to 2018, cases of paratyphoid fever were considered salmonellosis. ***** Includes the following categories: primary; secondary; early non-primary non-secondary (includes cases previously reported as early latent); unknown duration or late (includes cases previously reported as late latent syphilis and cases previously reported as late syphilis with clinical manifestations) and congenital syphilis. ††††† Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. Data for congenital syphilis are aggregated by the infant's year of birth. §§§§§ Vancomycin-resistant Staphylococcus aureus cases reported in this table may not have been verified by CDC. CDC verified 0 vancomycin-resistant Staphylococcus aureus cases in 2022. ¶¶¶¶¶ Beginning in January 2022, Chapare virus was added as a nationally notifiable condition, and confirmed and suspect cases combined are published to align with the approved CSTE position statement 21-ID-04. ****** Beginning in January 2022, confirmed and suspect cases combined are published to align with the approved CSTE position statement 21-ID-04, whereas in previous years, only confirmed cases were published. †††††† Data reported to ArboNET using the national surveillance case definition for congenital Zika virus infection (CSTE Position Statement 16-ID-01). Notes: These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables. Source datasets for the 2022 annual tables were officially closed on March 29, 2024. The list of national notifiable Infectious diseases and conditions for 2022 and their national surveillance case definitions are available by navigating to the https://ndc.services.cdc.gov/, Surveillance Case Definitions | CDC web page, selecting "2022" for the notifiable condition list year, checking "Infectious" conditions, and clicking "Get Notifiable List by Year". Publication criteria for the finalized 2022 data are available at https://wonder.cdc.gov/nndss/documents/NNDSS_Publication_Criteria_2022.pdf, https://wonder.cdc.gov/nndss/documents/NNDSS_Publication_Criteria_2022.pdf. See also https://www.cdc.gov/nndss/data-statistics/readers-guides/index.html, Guide to Interpreting Provisional and Finalized NNDSS Data. Population estimates for incidence rates are July 1st, 2022 postcensal estimates of the resident population of the United States for July 1, 2020, to July 1, 2022, by year, county, single year of age (range: 0 to 85+ years), bridged-race (American Indian or Alaska Native, Asian or Pacific Islander, Black or African American, White), Hispanic ethnicity (Hispanic or Latino, not Hispanic or Latino), and sex (Female, Male), prepared under a collaborative arrangement with the U.S. Census Bureau and the National Cancer Institute (NCI). The "Vintage 2022" population estimates for years 2020-2022 were released March 2024 by the National Cancer Institute at https://seer.cancer.gov/popdata/">https://seer.cancer.gov/popdata/. For more information, see Population estimates for territories are the 2022 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on May 02, 2024, at https://www.census.gov/data-tools/demo/idb/#/country?YR_ANIM=2022, https://www.census.gov/data-tools/demo/idb/#/country?YR_ANIM=2022. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation. Annual tables for 2016 and later years are available on https://wonder.cdc.gov/nndss/nndss_annual_tables_menu.asp, CDC WONDER. Annual summary reports from 1993–2015 are available as published in the https://www.cdc.gov/mmwr/mmwr_nd/index.html, Morbidity and Mortality Weekly Report. NNDSS annual tables since 1952 are available at https://stacks.cdc.gov/, CDC Stacks. To find them, search for "NNDSS" under Collections. Once in NNDSS Collections, navigate to the "Genre" box on the left-hand side and select "Annual Reports". For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a national notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations. Age restrictions in the numerator and denominator are applied for the following childhood conditions: Zika virus disease, congenital (age restriction in numerator and denominator is <1 year) Zika virus infection, congenital (age restriction in numerator and denominator is <1 year) Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years) Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years) Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years) Infant botulism (age restriction in numerator and denominator is <1 year) Congenital rubella syndrome (age restriction in numerator and denominator is <1 year) Perinatal hepatitis B infection (age restriction is ≤24 months) Perinatal hepatitis C infection (age restriction is ≤36 months). Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2022 (National Center for Health Statistics https://wonder.cdc.gov/natality.html, Natality 2022, as compiled from data provided by the Vital Statistics Cooperative Program). Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC). Disease data presented in the 2022 tables reflect impacts of the COVID-19 pandemic, such as changes in exposure-related behavior, healthcare-seeking behavior, disease reporting, and public health investigations. Suggested Citation: Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, 2022 Annual Tables of Infectious Disease Data. Atlanta, GA. CDC Office of Public Health Data, Surveillance, and Technology, 2024. Available at: https://www.cdc.gov/nndss/data-statistics/infectious-tables/index.html, https://www.cdc.gov/nndss/data-statistics/infectious-tables/index.html. Acknowledgment: CDC acknowledges the local, state, and territorial health departments that collected the data from a range of case ascertainment sources (e.g., healthcare providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System. https://www.cdc.gov/nndss/, National Notifiable Diseases Surveillance System Provided by https://wonder.cdc.gov, CDC WONDER